combination therapy

1:17
First-line treatment of SAA: towards a new standard of care?
Regis Peffault de Latour
4:32
Improving outcomes in FLT3-mutated AML patients
Naval Daver
2:06
Venetoclax and ibrutinib for R/R CLL: analysis from the VIsion/HO141 trial
Arnon Kater
1:28
Venetoclax resistance in CLL
Arnon Kater
1:25
ANCHOR study updates
Enrique Ocio
3:23
Upcoming updates in multiple myeloma
Thierry Facon
5:51
Major CLL updates from EHA 2019
Patrick Thornton
4:09
ADCs for AML: potential alternatives to gemtuzumab ozogamicin
Naval Daver
2:07
ADCs for AML: gemtuzumab ozogamicin
Naval Daver
2:57
Venetoclax and FLT3 inhibitor combination therapy for AML
Naval Daver
11:06
The future treatment of acute leukemias: part I
Alan Burnett et al.
19:48
The future treatment of acute leukemias: part II
Alan Burnett et al.
1:58
Top CLL news summer 2019
Lydia Scarfò
1:30
Moving to the frontline: gilteritinib plus chemo for newly diagnosed AML
Alexander Perl
2:04
Rapid development in the CLL treatment landscape
Peter Hillmen
3:15
New horizons in CML
Gianantonio Rosti
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals